TrialAnnals of the rheumatic diseases2018

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).

Yoshikazu Nakaoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.